APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

被引：0
|
作者：
Necchi, A. [1 ]
Mariani, L. [2 ]
Anichini, A. [3 ]
Giannatempo, P. [1 ]
Raggi, D. [1 ]
Togliardi, E. [4 ]
Calareso, G. [5 ]
Di Genova, N. [1 ]
Crippa, F. [6 ]
Salvioni, R. [7 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Expt Oncol & Mol Med, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Pharm Unit, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Radiol, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Nucl Med & PET Unit, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Surg Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
    Shen, Lin
    Gong, Jifang
    Zhang, Jian
    Ji, Dongmei
    Zhong, Haijun
    Yuan, Ying
    Yang, Lei
    Zhang, Qingyuan
    Li, Yufeng
    Wang, Mengde
    Qi, Chuan
    Xia, Zhenzhong
    Lu, Lingmin
    Huang, John
    Sun, Ling
    Xu, Li
    Shi, Michael
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Zalcman, G.
    Rizvi, N. A.
    Lena, H.
    Wolf, J.
    Mazieres, J.
    Antonia, S. J.
    Minenza, E.
    Planchard, D.
    Lestini, B. J.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2015, 26
  • [44] AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
    Wang, F.
    Lin, C-Y.
    Sun, J-M.
    Lu, C-H.
    Zhu, X.
    Chen, Z.
    Kim, I-H.
    Pan, Y.
    Zhang, J.
    Chen, Z.
    Tougeron, D.
    Kim, S-B.
    Van Cutsem, E.
    Abdrashitov, R.
    Ge, R.
    Sun, J.
    Zhou, J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S621 - S621
  • [45] Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies
    Wang, Kun
    Pan, Chaohsuan
    Xu, Fengyan
    Tse, Archie N.
    Sheng, Yucheng
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 91 (03) : 748 - 760
  • [46] Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Rosenbaum, Eli
    Culine, Stephane
    Burgess, Earle Frederick
    O'Donnell, Peter H.
    Tagawa, Scott T.
    Zakharia, Yousef
    OHagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    Santiago-Walker, Ademi E.
    Roccia, Tito
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy
    Hsu, M. L.
    Ge, W.
    Wu, N.
    Quek, R.
    Liu, J.
    Jalbert, J. J.
    Rietschel, P.
    Feliciano, J.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1056 - S1056
  • [48] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
    Amin, Asim
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Medina, Theresa Michelle
    Conry, Robert Martin
    Lao, Christopher D.
    Daniels, Gregory A.
    Reddy, Sunil A.
    Andtbacka, Robert Hans Ingemar
    Barve, Minal A.
    Shaheen, Montaser F.
    Tueting, Thomas
    Chisamore, Michael Jon
    Schmidt, Emmett V.
    Candia, Albert
    Obiozor, Cynthia Chinedu
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
    Xing, Yan
    Chand, Gitasha
    Liu, Changchun
    Cook, Gary J. R.
    O'Doherty, Jim
    Zhao, Lingzhou
    Wong, Nicholas C. L.
    Meszaros, Levente K.
    Ting, Hong Hoi
    Zhao, Jinhua
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (09) : 1213 - 1220
  • [50] MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.
    Hu, Xichun
    Gong, Jifang
    Ji, Dongmei
    Shen, Lin
    Li, Yufeng
    Wang, Mengde
    Huang, Yingjie
    Xia, Zhenzhong
    Lu, Lingmin
    Huang, John
    Xu, Li
    Li, Jenny
    Wan, Yuntao
    Qian, Xueming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345